2018

Irene Headshot

Irene Min, PhD
Weill Cornell Medical College
Young Investigator Grant

NANETS congratulates Irene Min, PhD of Weill Cornell Medical College as the NANETS 2018 Young Investigator (YI) Award recipient.

Dr. Min received the grant for her proposal Analysis of Immune Environment for Targeting Metastatic Pancreatic Neuroendocrine Tumors. The goal of this study is to elucidate the tumor-immune networks in localized and metastatic pancreatic neuroendocrine tumors (PNETs) and to determine the effect of macrophage inhibitors on enhancing T cell proliferation in metastatic PNET mouse model.

The Young Investigator (YI) Grant is funded by Novartis International AG, a multinational pharmaceutical company based in Basel Switzerland. The $50,000 Young Investigator (YI) Grant is administered over the course of one year. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


julie hallet headshot 2

Julie Hallet, MD, MSc, FRCSC
Odette Cancer Center
Sunnybrook Health Sciences Centre
NCIS Grant

NANETS congratulates Julie Hallet, MD, MSc, FRCSC, of Odette Cancer Center, Sunnybrook Health Sciences Centre, as the 2018 NANETS Clinical Investigator Scholarship (NCIS) recipient. The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field. This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

The 2018 recipient, Dr. Julie Hallet, received this grant for her proposal An Evaluation of Patient Reported Outcomes, Patterns of Symptoms Severity, and Survival for Neuroendocrine Tumors. The focus of her program in health services population-based research is to examine process, patterns of care, and outcomes for neuroendocrine tumors (NETs) in order to improve care by identifying and establishing enablers to timely diagnosis and effective management.

She has conducted several projects documenting the epidemiology of NETs and exploring possible sources of care and outcome disparities. Using this previous work as background, support from the NCIS grant will allow her to further her research into process of care of NETs.

IPSEN is proud to sponsor the continuation of Edda’s work on behalf of NET patients through this Clinical Investigator Scholarship. IPSEN Biopharmaceuticals supports this research scholarship in the form of a $50,000 grant directed to NANETS to administer over the course of the one year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


Renata Headshot

Renata Jaskula-Sztul, PhD
University of Alabama at Birmingham
School of Medicine
BTSI Grant

NANETS congratulates Renata Jaskula-Sztul, PhD, of the University of Alabama at Birmingham, School of Medicine, as the NANETS 2018 Basic/Translational Science Investigator (BTSI) Award recipient.

Dr. Jaskula-Sztul received this grant for her proposal, Novel Antibody-Drug Conjugate (ADC) for Pancreatic Neuroendocrine Tumor (PanNET) Targeted Therapy. She has published more than 40 papers and, as a co-investigator, she has received funding for five research grants on targeted drug delivery to neuroendocrine tumors.

Dr. Jaskula-Sztul’s current project on testing antibody-drug conjugates as a potential drug for NET will generate new and exciting information that will form the foundation for future grants.

The Basic/Translational Science Investigator (BTSI) Grant is funded by the Neuroendocrine Tumor Research Foundation (NETRF). The $100,000 BTSI Grant is administered over the course of two years. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


thomas hope headshot 2

Thomas Hope, MD
University of California San Francisco
San Francisco Veterans Affairs Medical Center
NTIG Grant

NANETS congratulates Thomas Hope, MD, of the University of California San Francisco and San Francisco Veterans Affairs Medical Center, as the 2018 NANETS' Theragnostics Investigator Grant (NTIG) recipient. The NTIG is intended to push forward the boundaries of molecularly targeted radionuclide therapy and diagnostics for patients with neuroendocrine tumors.

The 2018 recipient, Dr. Thomas Hope, received this grant for his proposal Optimization of Intra-Arterial Y90-DOTATOC PRRT. He will use the funds to continue his work with Y90-DOTATOC using intra-arterial administration, which is an important therapeutic route for peptide receptor radionuclide therapy (PRRT)-Optimization of Intra-Arterial Y90-DOTATOC PRRT. This grant will also provide significant insight into the issues related to receptor saturation, which is not a well-addressed limitation to improving PRRT treatment.

Dr. Hope is an Associate Professor in Residence in the Abdominal Imaging and Nuclear Medicine sections at UCSF and the San Francisco Veterans Affairs Medical Center. He has published 60 peer-reviewed articles, including 21 first author publications.

Advanced Accelerator Applications (AAA) is proud to sponsor this research scholarship in the form of a $100,000 grant directed to NANETS to administer over the course of the two year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


2017

Brian Untch MD

Brian Untch, MD
Memorial Sloan Kettering Cancer Center
BTSI Grant

NANETS congratulates Brian Untch, MD of Memorial Sloan Kettering Cancer Center as the NANETS 2017 Basic Translational Science Investigator (BTSI) Award recipient.

Dr. Untch proposed to explore new approaches for treating neuroendocrine cancers. The award will fund Dr. Untch’s work assessing the effectiveness of peptide receptor radionuclide therapy (PRRT), which targets somatostatin receptors in mouse models of neuroendocrine cancer. Somatostatin receptor ligands such as DOTA-TATE have been established as effective tools for detection of neuroendocrine tumors such as those found in pancreatic and gut cancers. However, these detection agents are now also being considered for their potential as treatments. This new field of “theragnostics” holds promise as an approach that may be combined with other classes of drugs to more effectively treat neuroendocrine cancers. Indeed, Dr. Untch’s research includes assessing the combined effects of PRRT and other promising chemotherapeutic approaches. The potential of these studies to have an impact on neuroendocrine cancer treatment, together with the strength of Dr. Untch’s investigator/mentor team and institution, convinced NANETS that this was the project to support with this year’s award.

The BTSI is sponsored by the Neuroendocrine Tumor Research Foundation (NETRF) and is made possible by the generous support of the Margie and Robert Peterson Foundation. The BTSI is awarded to a NANETS member in their first five years of faculty appointment and is meant to encourage the pursuit of basic or translational research with a focus on neuroendocrine tumors. The BTSI is a grant award of $100,000 to be distributed over the two year grant award cycle.


Etay Ziv MD

Etay Ziv, MD, PhD
Memorial Sloan Kettering Cancer Center
NCIS Grant

NANETS congratulates Etay Ziv, MD, PhD of Memorial Sloan Kettering Cancer Center as the 2017 NANETS Clinical Investigator Scholarship recipient. The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field. This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

The 2017 recipient, Dr. Etay Ziv, seeks to improve the outcome of patients undergoing liver directed therapy of pancreatic neuroendocrine tumor liver metastases. Dr. Ziv will evaluate whether the molecular biomarker, DAXX mutation, is a predictor of poor response to liver-directed therapy. This work has the potential to identify which patients will most likely benefit from treatment and to provide insight into why patients may or may not respond to treatment.

IPSEN is proud to sponsor the continuation of Edda’s work on behalf of NET patients through this Clinical Investigator Scholarship. IPSEN Biopharmaceuticals supports this research scholarship in the form of a $100,000 grant directed to NANETS to administer over the course of the two year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.

2016

Christopher M. Heaphy, PhD
Johns Hopkins University
School of Medicine
BTSI Grant

NANETS congratulates Christopher M. Heaphy, PhD of Johns Hopkins University School of Medicine as the NANETS 2016 Basic Translational Science Investigator (BTSI) Award recipient. The BTSI is sponsored by the Neuroendocrine Tumor Research Foundation (NETRF) and is made possible by the generous support of the Margie and Robert Peterson Foundation. The BTSI is awarded to a NANETS member in their first five years of faculty appointment and is meant to encourage the pursuit of basic or translational research with a focus on neuroendocrine tumors. The BTSI is a grant award of $100,000 to be distributed over the two-year grant award cycle. Dr. Heaphy plans to utilize the BTSI award to invest in his translational research to further the understanding of pancreatic neuroendocrine tumor biology.

Claudius Conrad, MD, PhD
University of Texas
MD Anderson Cancer Center
NCIS Grant

NANETS congratulates Claudius Conrad, MD, PhD of The University of Texas MD Anderson Cancer Center as the 2016 NANETS Clinical Investigator Scholarship recipient. The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field. This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors. The 2016 recipient, Dr. Claudius Conrad will continue his focus on the treatment of patients with pancreatic neuroendocrine tumors and neuroendocrine liver metastasis.

IPSEN is proud to sponsor the continuation of Edda’s work on behalf of NET patients through this Clinical Investigator Scholarship. IPSEN Biopharmaceuticals supports this research scholarship in the form of a $100,000 grant directed to NANETS to administer over the course of the two year grant period. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


2015

Bryson Katona, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Young Investigator Grant

NANETS congratulates Bryson William Katona as the 2015 Young Investigator grant recipient for his work on ER stress and the unfolded protein response in neuroendocrine tumor proliferation.

Despite many recent advances in the field of neuroendocrine tumors, there still remains a critical need to develop novel therapeutic approaches to better treat these tumors. Within the distinct genetic landscape of neuroendocrine tumors, the focus of my project is to better understand the role of ER stress and the unfolded protein response in neuroendocrine tumor proliferation and resistance to chemotherapy. The ultimate goal of this project will be to develop novel methods to selectively target ER stress pathways to improve current treatment paradigms for the treatment of neuroendocrine tumors.

Dr. Katona conducts his research in a cancer biology lab focusing on menin. He was awarded a $50,000 grant, sponsored by Novartis Oncology and NANETS, to pursue basic science/translational research focused on neuroendocrine tumors.


Arvind Dasari, MD
MD Anderson Cancer Center
NCIS Grant

The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendocrine tumor field. Dr. Dasari is an ideal candidate and his research proposal and objectives show great potential. This award is in honor of Edda Gomez-Panzani, MD for her dedication and work on behalf of patients living with neuroendocrine tumors.

In discussing his plan, Dr. Dasari said, “Neuroendocrine tumors, NETs, are lethal when advanced with limited treatment options, in large part due to lack of adequate understanding of the underlying molecular aberrations. Overwhelming evidence point towards dysregulation of the retinoblastoma pathway (and thus cyclin-dependent kinases, 4,6 CDK 4/6) in the majority of foregut NETs. Our goal in the current study is to demonstrate activity of CDK 4/6 inhibitors in foregut NETs by: 1) conducting pharmacodynamic (PD) and correlative studies on paired biopsies from a clinical trial of patients with foregut NETs treated with an oral CDK 4/6 inhibitor, 2) determining activity of mTOR inhibitor with an oral CDK 4/6 inhibitor in xenograft models of NETs."

IPSEN is proud to sponsor the continuation of Edda’s work on behalf of NET patients through this Clinical Investigator Scholarship. IPSEN Biopharmaceuticals supports this research scholarship in the form of a $50,000 grant directed to NANETS to administer. The NANETS Research Committee establishes the award criteria, reviews process, and independently selects the recipient.


2014

Jennifer Eads, MD
University Hospitals
Young Investigator Grant

Jennifer Eads, MD, is an Assistant Professor, Division of Hematology and Oncology, Department of Medicine at University Hospitals Cleveland Medical Center.

She is board certified in internal medicine and medical oncology.

Dr. Eads’ special interests include gastrointestinal oncology including cancers of the esophagus and stomach, pancreas, gallbladder and bile ducts and gastrointestinal neuroendocrine tumors. She joined the UH Cleveland Medical Center staff in 2009.

Dr. Eads’ research interests include understanding the role of DNA repair in neuroendocrine tumors and esophageal cancers. She is currently the Principal Investigator on several clinical trials related to gastrointestinal malignancies including esophageal cancer, pancreatic cancer, gallbladder and bile duct cancer and multiple types of neuroendocrine tumors.


2013

Hala Elnakat Thomas, PhD
University of Cincinnati
School of Medicine
Young Investigator Grant

NANETS congratulates Hala Elnakat Thomas as the 2013 Young Investigator Grant Recipient for her work on mTOR inhibition in the treatment of pNETs.

Because the allosteric inhibitor of the mammalian Target Of Rapamycin (mTOR), everolimus (RAD001), has already shown efficacy in pancreatic neuroendocrine tumors (pNETs), it is compelling to assess in this indication, the ability of the next-generation mTOR inhibitors to impede tumor progression. Toward this end, BEZ235 a dual phosphatidylinositide-3OH kinase (PI3K)/mTOR inhibitor is currently being evaluated as a single agent in a number of phase I/II clinical trials for treatment of patients with pNETs either prior to or after failure of allosteric mTOR inhibitors. Based on my previous work, I predict that a major benefit of treating pNETs with RAD001 in combination with BEZ235 will be a synergistic inhibition of mTOR at lower doses of each drug, which will increase specificity while decreasing toxicity. The preclinical data generated from this award will not only improve our molecular and mechanistic understanding of the drug combination but will more importantly potentially improve the clinical outcome for pNET patients treated with RAD001 and BEZ235 in combination in lieu of either drug as a single agent.


Katherine Van Loon, MD, MPH
University of California
San Fransisco
NCIS Grant

NANETS congratulates NCIS recipient Katherine VanLoon, MD, MPH. She plans to use the robust database available from the NCCN’s multi-institutional Neuroendocrine Tumor Outcomes Project to report recurrence rates, time to tumor recurrence, and survival for patients with gastroenteropancreatic neuroendocrine tumors (NETs) who undergo surgical resection with curative intent.

Because NCCN guidelines for surveillance imaging following resection are vague and reflect lack of standardization, I will describe the surveillance practices of the member institutions for patients who undergo complete surg ical resection of gastroenteropancreatic NETs. This analysis will attempt to identify patient subgroups at particularly high risk of recurrence following surgical resection of gastroenteropancreatic NETs.


2012

Lauren Fishbein, MD, PhD
University of Colorado
School of Medicine
Early Career Development Grant

On behalf of The North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce the selection of Lauren Fishbein, MD, PhD, as the recipient of the 2012 Early Career Development award in the amount of $50,000.

Her research proposal is titled “Somatic Mutations in Pheochromocytomas and Paragangliomas” and proposes to use cutting edge “next generation” sequencing techniques to identify somatic mutations which contribute to tumorigenesis or malignant transformation.
Dr. Fishebein says "Our hope is to determine if distinct patterns of somatic mutations are associated with different inherited mutations. Since pheochromocytomas and paragangliomas are tumors associated with high morbidity and mortality with limited treatments for recurrent or metastatic disease, it is critical to understand tumorigenesis in order to identify novel molecular markers for future therapeutic targets."

This award is supported by Novartis with the goal to improve patient outcomes in NETs. This collaborative partnership and the assistance of Novartis in funding research will be a critical component of improving the lives of people with carcinoid/NET cancers. Their continued support and commitment to assist NANETS in fulfilling our mission is critical to the success of the NANETS organization.


2011

Karine Pozo, PhD, MSc
UT Southwestern Medical Center
Early Career Development Grant

Congratulations to Karine Pozo, PhD, MSc. On behalf of The North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce the selection of Karine Pozo, PhD, as the recipient of one of the 2011 Early Career Development awards in the amount of $50,000.

Her research proposal, entitled “Identification of new RET-associated signaling mechanisms in medullary thyroid carcinoma (MTC)” is focusing on the protein kinase, cyclin-dependent kinase 5 (Cdk5), and its activating cofactor, p25 which has recently been implicated in medullary thyroid carcinoma (MTC) oncogenesis and proliferation.
Dr. Pozo says, “The aim of this study is to delineate the role of p25/Cdk5 in the activation of RET signaling cascade and subsequent mechanisms leading to MTC tumorigenesis. This work will lead to the identification of novel targets on which to base the development of treatments for MTC."

This award is supported by Ipsen with the goal to improve patient outcomes in NETs. This collaborative partnership and the assistance of Ipsen in funding research will be a critical component of improving the lives of people with carcinoid/NET cancers. Their continued support and commitment to assist NANETS in fulfilling our mission is critical to the success of the NANETS organization.


TaeHeeKim

Tae-Hee Kim, PhD
The Hospital for Sick Kids (SickKids)
Early Career Development Grant

Congratulations to Tae-Hee Kim, PhD! His research proposal "Transcriptional regulation of intestinal secretory cell differentiation through Atoh1 and Tcf4" will address the need to better understand the cells from which intestinal neuroendocrine (carcinoid) tumors originate to help in the development of targeted therapies.
On behalf of the North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce his selection as the recipient of one of our 2011 Early Career Development grants in the amount of $50,000. Following is Dr. Kim’s summary of his project:

"The treatment and cure of neuroendocrine tumors require an accurate and deep understanding of the molecular processes that govern normal endocrine cell behavior. These cells originate in intestinal crypt stem cells and my research program focuses on studying the molecular mechanisms of secretory (endocrine) cell differentiation. In this proposal, I emphasize the roles of two important proteins, Atoh1 and Tcf4. These proteins are transcription factors, i.e., proteins that control hundreds of other genes, and I propose to study how these proteins do so. My work will, therefore, help advance understanding of fundamental mechanisms and therapeutic targets in neuroendocrine tumors.”
Due to the current shortage of young scientists focused on the clinical investigation of neuroendocrine tumors, we created this grant to encourage physicians, at the end of their fellowship or beginning of their faculty appointment, to pursue clinical or translational research in this field. Dr. Kim’s application was well written and his research plan has the capability of producing results that would make significant contributions to NET research and lead to a productive career in neuroendocrine tumors."

In addition, we want to acknowledge Novartis Oncology for funding this grant. Their continued support and commitment to assist NANETS in fulfilling our mission is critical to the success of the NANETS organization. This collaborative partnership and their assistance in funding research will continue to make a positive impact in improving the lives of people with carcinoid/NET cancers.


2010

Mei Dong, MD, PhD
Cancer Care Northwest
Young Investigator Grant

Congratulations to Mei Dong, MD, PhD. On behalf of The North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce the selection of Mei Dong, MD, PhD as the recipient of one of the 2010 Young Investigator awards in the amount of $50,000.

Her research proposal, entitled “Role of Hedgehog Pathway in Gastrointestinal Neuroendocrine Tumorigenesis" is focusing on the well-known premise that a significant amount of patients with NETs may have harbored the slow-growing lesions since a very young age, which suggests it could result from alterations of pathways involved in development. Hedgehog (Hh) signaling has been found to be important in embryonic patterning, stem cell maintenance and tissue repair; and is normally silenced in most mature adult tissue. This innovative strategy will investigate this signaling pathway as a target in the tumorigenesis of NETs and their development.

"The goal of the proposed project is to study the role of Hedgehog signaling pathway in neuroendocrine tumorigenesis and its potential as a therapeutic target,” said Dr. Dong.

More broadly, the Young Investigator Award helps address a current shortage of young scientists focused on the investigation of neuroendocrine tumors and is open to investigators at the end of their fellowship or beginning of their faculty appointment.

This award is supported by Ipsen with the goal to improve patient outcomes in NETs. This collaborative partnership and the assistance of Ipsen in funding research will be a critical component of improving the lives of people with carcinoid/NET cancers.

Dr. Dong will be presenting developments from this research project at the NANETS annual meeting in 2011.


Haggi Mazeh, MD
Hadassah Medical Center
Early Career Development Grant

Congratulations to Haggi Mazeh, MD! His research proposal "The Role of Notch 1, 2 and 3 in Neuroendocrine Tumors” will address the need for development of other forms of therapy for NET cancers by characterizing the roles of the Notch isoforms in regulating NE cancer cell growth and hormone secretion.

On behalf of the North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce his selection as the recipient of one of our 2010 Young Investigator grants in the amount of $50,000. Following is Dr. Mazeh's summary of his project:

"It has previously been shown that Notch 1 markedly suppresses NE tumor cell growth and hormone production. The aim of this study is to investigate the role of Notch 2 & 3 in regulating NE cancer proliferation and hormone secretion in vitro. Furthermore, the affects of Notch 2 & 3 activation on NE cancer progression and hormone production in vivo will be determined. "
Due to the current shortage of young scientists focused on the clinical investigation of neuroendocrine tumors, we created this grant to encourage physicians, at the end of their fellowship or beginning of their faculty appointment, to pursue clinical or translational research in this field. Dr. Mazeh's application was well written and his research plan has the capability of producing results that would make significant contributions to NET research and lead to a productive career in neuroendocrine tumors.

In addition, we want to acknowledge the Novarits Oncology for funding this grant. Their continued support and commitment to assist NANETS in fulfilling our mission is critical to the success of the NANETS organization. This collaborative partnership and their assistance in funding research will continue to make a positive impact in improving the lives of people with carcinoid/NET cancers.

Dr. Mazeh will be presenting developments from this research project at the NANETS annual meeting in 2011.


2009

Diane Reidy-Lagunes, MD, MS
Memorial Sloan Kettering
Cancer Center
Young Investigator Grant

On behalf of The North American Neuroendocrine Tumor Society (NANETS), it is a pleasure to announce the selection of Diane Reidy-Lagunes, M.D., M.S. as the recipient a Young Investigator award in the amount of $50,000. Her research proposal, entitled “A Novel Therapeutic Strategy to Identify the Pathways Driving Neuroendocrine Tumors & Improve Our Treatments: From Mouse Models to Human Patients” describes an innovative, collaborative strategy that brings together clinical and basic researchers to uncover and therapeutically target the pathways driving neuroendocrine tumor (NET) development.

“The project will help address current knowledge gaps by integrating the analysis of human NET samples with appropriate mouse models of NET cancer. Of particular interest is Dr. Reidy-Lagunes’ approach of testing specific, novel targeted therapies in the mouse model to speed their path to the clinic. “We will move back and forth between human and animal studies, which will continuously cross-inform each other, with the ultimate goal of rapidly translating the knowledge we gain into a novel and effective treatments for this disease,” said Dr. Reidy.

More broadly, the Young Investigator Award helps address a current shortage of young scientists focused on the investigation of neuroendocrine tumors and is open to investigators at the end of their fellowship or beginning of their faculty appointment. The award was supported by The NET Alliance, a long-term commitment by Novartis Oncology, with the goal of improving patient outcomes in NETs. This collaborative partnership and the assistance of Novartis in funding research will be a critical component of improving the lives of people with carcinoid/NET cancers.

Dr. Reidy-Lagunes will be presenting developments from this research project at the NANETS annual meeting in 2010.


Hans Kumar Ghayee, DO
University of Florida Health
Early Career Development Grant

Congratulations to Dr. Hans Ghayee! His research proposal "mTOR Inhibitors Effect on Growth & Catecholalmine Synthesis of Human Pheochromocytoma Cells" is a distinctive concept of developing a new pheochromocytoma cell line and of testing new agents in that cell line which has the potential of being highly relevant to the field.

On behalf of the North American Neuroendocrine Tumor Society (NANETS) it is a pleasure to announce his selection as the recipient of our first Young Investigator grant in the amount of $50,000. Following is Dr. Gahyee summary of his project:

"Our group is interested in studying tumors called pheochromocytoma that arise from the adrenal medulla. These tumors secrete catecholamines and affected patients may present with hypertension or palpitations and can have devastating complications resulting in cardiovascular collapse. We are interested in identifying compounds which might inhibit pheochromocytoma cell proliferation or catecholamine production. One such candidate class of compounds are called mTOR inhibitors. We hope to further investigate whether hypersecretion of catecholamines would be controlled with mTOR inhibitors. A human pheochromocytoma cell line has been generated in our laboratory and affords us an opportunity to study the effects of mTOR inhibitors and other drugs on human pheochromocytoma cells which will give us an insight for future therapeutic targets."

Due to the current shortage of young scientists focused on the clinical investigation of neuroendocrine tumors, we created this grant to encourage physicians, at the end of their fellowship or beginning of their faculty appointment, to pursue clinical research in this field. Dr. Ghayee's application was well written and his research plan has the capability of producing results that would make significant contributions to NET research and lead to a productive career in neuroendocrine tumors.

In addition, we want to acknowledge the Carcinoid Cancer Foundation for funding this grant. Their continued support and commitment to assist NANETS in fulfilling our mission is critical to the success of the NANETS organization. This collaborative partnership and their assistance in funding research will continue to make a positive impact in improving the lives of people with carcinoid/NET cancers.

Dr. Ghayee will be presenting developments from this research project at the NANETS annual meeting in 2010.